Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798556 | 0.79 | CYP19A1 (0.46) | CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL3791450 | 0.76 | CYP19A1 (0.51) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 | |
| SCHEMBL73676 | 0.76 | CYP2A6 (0.60) | CYP2A6 | |
| SCHEMBL19203790 | 0.75 | ICAM1 (0.42) | CYP19A1TBXAS1 | |
| SCHEMBL2548724 | 0.75 | CYP19A1 (0.34) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 | |
| SCHEMBL2092142 | 0.75 | CYP19A1 (0.46) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 | |
| SCHEMBL30287240 | 0.75 | CYP2A6 (0.59) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 | |
| SCHEMBL3150232 | 0.75 | CYP2A6 (0.59) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 | |
| SCHEMBL506756 | 0.75 | CYP2A6 (0.57) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 | |
| SCHEMBL22627566 | 0.74 | GABRA1 (0.47) | CYP19A1TBXAS1OPRM1OPRK1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CYP19A1 1294/4885TBXAS1 573/4885OPRM1 4058/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CYP19A1 1294/4885TBXAS1 573/4885OPRM1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.